Albert DH - Search Results

1

ABT-491, a highly potent and selective PAF antagonist, inhibits nasal vascular permeability associated with experimental allergic rhinitis in brown Norway rats.

Albert DH, Tapang P, Morgan DW, Curtin ML, Sheppard GS, Davidsen SK, Summers JB, Carter GW. Albert DH, et al. Inflamm Res. 1997 Aug;46 Suppl 2:S133-4. doi: 10.1007/s000110050141. Inflamm Res. 1997. PMID: 9297547 No abstract available.

2

ABT-299, a potent antagonist of platelet activating factor.

Summers JB, Albert DH, Davidsen SK, Conway RG, Holms JH, Magoc TJ, Luo G, Tapang P, Rhein DA, Carter GW. Summers JB, et al. Among authors: albert dh. Adv Prostaglandin Thromboxane Leukot Res. 1995;23:475-7. Adv Prostaglandin Thromboxane Leukot Res. 1995. PMID: 7732895 No abstract available.

3

Properties of ABT-299, a prodrug of A-85783, a highly potent platelet activating factor receptor antagonist.

Albert DH, Conway RG, Magoc TJ, Tapang P, Rhein DA, Luo G, Holms JH, Davidsen SK, Summers JB, Carter GW. Albert DH, et al. J Pharmacol Exp Ther. 1996 Jun;277(3):1595-606. J Pharmacol Exp Ther. 1996. PMID: 8667228

4

ABT-299, a novel PAF antagonist, attenuates multiple effects of endotoxemia in conscious rats.

Albert DH, Luo G, Magoc TJ, Tapang P, Holms JH, Davidsen SK, Summers JB, Carter GW. Albert DH, et al. Shock. 1996 Aug;6(2):112-7. doi: 10.1097/00024382-199608000-00006. Shock. 1996. PMID: 8856845

5

Pharmacology of ABT-491, a highly potent platelet-activating factor receptor antagonist.

Albert DH, Magoc TJ, Tapang P, Luo G, Morgan DW, Curtin M, Sheppard GS, Xu L, Heyman HR, Davidsen SK, Summers JB, Carter GW. Albert DH, et al. Eur J Pharmacol. 1997 Apr 23;325(1):69-80. doi: 10.1016/s0014-2999(97)00109-x. Eur J Pharmacol. 1997. PMID: 9151941

6

Ex vivo inhibition of beta-thromboglobulin release following administration to man of ABT-299, a novel prodrug of a potent platelet activating factor antagonist.

Albert DH, Magoc TJ, Menacherry SD, Morgan DW, Sun E, Reyes AE, Kleinert HD, Carter GW, Summers JB. Albert DH, et al. Inflamm Res. 1997 Jul;46(7):272-7. doi: 10.1007/s000110050186. Inflamm Res. 1997. PMID: 9266276 Clinical Trial.

7

The role of platelet-activating factor (PAF) and the efficacy of ABT-491, a highly potent and selective PAF antagonist, in experimental allergic rhinitis.

Albert DH, Malo PE, Tapang P, Shaughnessy TK, Morgan DW, Wegner CD, Curtin ML, Sheppard GS, Xu L, Davidsen SK, Summers JB, Carter GW. Albert DH, et al. J Pharmacol Exp Ther. 1998 Jan;284(1):83-8. J Pharmacol Exp Ther. 1998. PMID: 9435164

8

ABT-869, a multitargeted receptor tyrosine kinase inhibitor, reduces tumor microvascularity and improves vascular wall integrity in preclinical tumor models.

Jiang F, Albert DH, Luo Y, Tapang P, Zhang K, Davidsen SK, Fox GB, Lesniewski R, McKeegan EM. Jiang F, et al. Among authors: albert dh. J Pharmacol Exp Ther. 2011 Jul;338(1):134-42. doi: 10.1124/jpet.110.178061. Epub 2011 Apr 19. J Pharmacol Exp Ther. 2011. PMID: 21505059

9

Synthesis and structure-activity relationships of a series of novel benzopyran-containing platelet activating factor antagonists.

Guinn DE, Summers JB, Heyman HR, Conway RG, Rhein DA, Albert DH, Magoc T, Carter GW. Guinn DE, et al. Among authors: albert dh. J Med Chem. 1992 May 29;35(11):2055-61. doi: 10.1021/jm00089a016. J Med Chem. 1992. PMID: 1317924

10

Platelet activating factor antagonists.

Summers JB, Albert DH. Summers JB, et al. Among authors: albert dh. Adv Pharmacol. 1995;32:67-168. doi: 10.1016/s1054-3589(08)61012-1. Adv Pharmacol. 1995. PMID: 7748804 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

89 results

Search Page

Filters